Esophagitis News and Research

RSS

Erosive GERD treatments: an interview with Professor Joaquim Moraes-Filho, University of São Paulo Medical School

Gastroesophageal Reflux Disease (GERD) is a condition that develops when the reflux of stomach contents causes troublesome symptoms and/or complications.

20 Jan 2014

Two on-the-rise esophagus conditions can be the result of food allergy, say doctors

Researchers at the UNC School of Medicine found that two on-the-rise esophagus conditions are so similar that even a biopsy is not enough to distinguish one disease from the other.

17 Dec 2013

Brazilian study provides evidence to support effectiveness of Tecta in erosive GERD

Takeda Pharmaceuticals International GmbH announced today results showing pantoprazole magnesium 40 mg (Tecta) was as effective as esomeprazole 40 mg for achieving complete remission (defined as combined endoscopic healing and symptomatic relief) and the mucosal healing rate was high, whilst providing significantly higher symptom relief after 8 weeks.

13 Dec 2013

First molecular test developed to detect eosinophilic esophagitis

Researchers at Cincinnati Children's Hospital Medical Center have developed the first molecular test to diagnose eosinophilic esophagitis, a chronic upper gastrointestinal disorder. The incidence of EoE has skyrocketed since it was first characterized two decades ago.

22 Nov 2013

Viropharma announces financial results for third quarter 2013

ViroPharma Incorporated reported today its financial results for the third quarter ended September 30, 2013. Net sales were $113 million for the third quarter ended September 30, 2013, as compared to $91 million in the same three months of 2012.

31 Oct 2013

Palliative chemoradiation boosts survival, QoL in poor-prognosis NSCLC

C hemoradiation is superior to chemotherapy alone with respect to both survival and quality of life in patients with inoperable non-small-cell lung cancer, a phase III trial has found.

10 Oct 2013

EGS announced that enrollment for RESPECT study has surpassed company's original target

EndoGastric Solutions (EGS), the leader in endoluminal reconstructive treatment for gastroesophageal reflux disease (GERD), announced today that enrollment for the RESPECT study (Randomized EsophyX vs. Sham/Placebo Controlled Trial) is complete and has surpassed the company's original target of 120 patients.

9 Oct 2013

Boehringer signs agreement with Brigham to conduct long-term study program on oral anticoagulants

Boehringer Ingelheim, a research-based, global pharmaceutical company, today announced a multi-year agreement with Brigham and Women's Hospital, an internationally recognized teaching affiliate of Harvard Medical School known for its excellence in patient care, medical research and training of outstanding young health professionals.

17 Aug 2013

Viropharma announces financial results for second quarter of 2013

VIROPHARMA INCORPORATED (Nasdaq: VPHM) today announced financial results for the second quarter of 2013. Net sales were $104 million for the second quarter ended June 30, 2013 as compared to $95 million in the comparative period of 2012.

1 Aug 2013

Implications for treating some common food allergies

Food is an integral part of life; but, for some, it can be harmful. Allergic inflammation caused by inappropriate immune responses to some types of food has become a major public health issue. Over the past ten years, the prevalence of food allergies has increased by nearly 20 percent, affecting an estimated six million people in the U.S.

22 Jul 2013

AGA Research Foundation announces 2013 research scholars

The American Gastroenterological Association Research Foundation is pleased to announce its 2013 research scholars. This year's honorees are outstanding young gastroenterologists working toward independent careers in gastroenterology, hepatology or related areas, and with this award, their research time will be protected.

20 May 2013

Dabigatran decreases risk of recurrent venous thromboembolism

New findings from two double-blind, randomized trials, RE-MEDY and RE-SONATE, show that dabigatran 150 mg twice daily reduces the risk of recurrent venous thromboembolism (VTE).

21 Feb 2013

Eosinophilic inflammation of the esophagus relieved by diet

A diet that eliminates six food types has proved effective at inducing remission of eosinophilic esophagitis in adults, report researchers.

18 Feb 2013

Elemental diet may help adults with eosinophilic esophagitis

Results from a small study suggest that consumption of an elemental diet for 2–4 weeks results in a significant histologic improvement in adult patients with eosinophilic esophagitis.

14 Feb 2013

Updated U.S. prescribing information for Boehringer Ingelheim’s Pradaxa

Boehringer Ingelheim Pharmaceuticals, Inc. today announced that the U.S. prescribing information for Pradaxa (dabigatran etexilate mesylate) capsules was updated to include a contraindication related to use in patients with mechanical prosthetic heart valve replacement.

21 Dec 2012

Gestational age and size at birth affect risk of early diagnosis of esophagitis

Infants that are born preterm or with impaired growth have an increased risk of developing gastroesophageal reflux disease (GERD), possibly leaving them vulnerable to the development of esophageal adenocarcinoma later in life.

12 Dec 2012

Pradaxa use does not appear to increase serious bleeding

The U.S. Food and Drug Administration (FDA) today announced the results of a Mini-Sentinel assessment that indicates bleeding rates associated with new use of Pradaxa (dabigatran etexilate mesylate) capsules do not appear to be higher than bleeding rates associated with new use of warfarin, which is consistent with observations from the pivotal RE-LY trial.

4 Nov 2012